Quick answer
What do animal wound-healing studies show for TB-500? Almost all of the animal wound-healing literature was done with full-length thymosin β4 (43 amino acids), not with the TB-500 fragment (Ac-LKKTETQ, residues 17–23). Studies in rats reported faster re-epithelialization and contraction of full-thickness skin wounds with topical or intraperitoneal thymosin β4, and mouse corneal studies reported faster corneal re-epithelialization with reduced inflammatory mediators. Whether the fragment reproduces these results is a separate question that the cited papers do not answer. The TB-500 product is supplied for laboratory research use only.
TB-500 is often described through the wound-healing literature, so it is worth reading that literature in the original. This article summarizes the principal animal-model studies, lists the design details that matter (species, wound type, route, comparator, readout) and flags the central caveat about full-length protein versus fragment. It is a literature guide for researchers, not a statement about use in people or animals outside a laboratory protocol. The compound-level overview is the TB-500 research overview.
Thymosin β4 and the TB-500 fragment
Thymosin β4 is a 43-residue peptide best known as an actin-sequestering protein; reviews describe it as a multifunctional molecule with roles in cell migration, survival and tissue repair models (Huff et al., 2001; Goldstein et al., 2012). The actin-binding region lies in the central part of the sequence, around residues 17–23 (LKKTETQ), and mutation studies have examined the role of that region in actin binding (Sun et al., 1996). The product page lists TB-500 as the synthetic 17–23 fragment, Ac-LKKTETQ, formula C38H68N10O14, supplied as a 10 mg lyophilized powder with purity stated as ≥98% by HPLC.
That relationship is the key caveat. A conclusion about wound healing drawn from full-length thymosin β4 applies to the 43-residue protein. It may or may not apply to a seven-residue fragment, because the fragment lacks most of the sequence and any functions that depend on it. The sections below therefore describe what was done with thymosin β4, and the final section returns to the fragment question.
Rat dermal wound studies
The best-known report is a 1999 study of full-thickness wounds in rats. Thymosin β4 given topically or by the intraperitoneal route was reported to accelerate re-epithelialization and wound contraction compared with saline-treated controls, and the same paper reported increased cell migration in vitro (Malinda et al., 1999). The study established the main experimental template used in later work: a standardized full-thickness wound, a defined time course, blinded histological measurement of the epithelial gap and of contraction, and a vehicle control. The authors also reported effects in additional assays including an angiogenesis model.
The follow-up commentary from the same group summarized that thymosin β4 promoted angiogenesis, wound healing and hair follicle development in rodent models (Philp et al., 2004). It is a short summary and not an independent replication, which matters when counting how many separate groups support a claim.
Mouse corneal wound studies
A second line of work used the cornea, where re-epithelialization can be measured precisely by staining. A 2001 study reported that thymosin β4 promoted corneal wound healing in mice and modulated inflammatory mediators in vivo (Sosne et al., 2001). The corneal model is attractive because the endpoint is simple (area of epithelial defect over time), but results from it are specific to a tissue with very different structure, vascularization and inflammatory environment from skin. A finding there should be read as support for the general idea of enhanced epithelial migration, not as confirmation of the skin result.
| Study | Species and model | Material and route reported | Principal readouts reported |
|---|---|---|---|
| Malinda et al., 1999 | Rat, full-thickness dermal wound | Thymosin β4, topical and intraperitoneal | Re-epithelialization, wound contraction; in vitro migration |
| Sosne et al., 2001 | Mouse, corneal wound | Thymosin β4, as reported in the paper | Corneal re-epithelialization, inflammatory mediators |
| Philp et al., 2004 | Rodent models (commentary) | Thymosin β4 | Angiogenesis, wound healing, hair follicle development |
Details of dose, vehicle and timing belong to the original papers and are not reproduced here; they are specific to those experiments and should be read there.
Design elements to compare across studies
Reading across animal wound-healing papers, the same design questions decide how much weight a result deserves. Differences in any of them can change the apparent effect size.
- Wound type. Full-thickness excisional, partial-thickness, incisional, burn and corneal wounds heal by different mechanisms.
- Splinting. Rodent skin heals largely by contraction, so unsplinted wounds are a poor model of human-like re-epithelialization. Studies that splint the wound isolate epithelial and granulation processes.
- Route. Topical, local and systemic routes deliver different exposures at the wound.
- Comparator. Vehicle-only controls are essential; a positive control with a known effect improves interpretation.
- Readout. Planimetry of wound area, histological epithelial gap, granulation tissue thickness and vessel density each measure something different.
- Blinding and sample size. Wound studies with small groups and unblinded scoring overstate effects.
A checklist like this is more informative than a headline conclusion, and it applies equally to any peptide tested in an animal wound model. For related background on tissue-response models, see the TB-500 overview and the BPC-157 overview.
Mechanistic candidates from in vitro work
Animal wound studies measure outcomes, not mechanisms, so the proposed mechanisms come from cell work. Thymosin β4 binds monomeric actin and regulates the pool of polymerizable actin, which is central to cell motility (Huff et al., 2001). Work on the actin-binding sequence showed that the region corresponding to the TB-500 fragment contributes to this interaction, and that thymosin β4 is not simply a passive buffer of actin monomers (Sun et al., 1996). Reports describing effects on cell migration, survival and angiogenesis in culture (Malinda et al., 1999; Philp et al., 2004) are the other pillar. These are candidates: they show that a mechanism is plausible, not that it operates in an intact wound.
Inflammatory modulation is a further candidate, because the corneal study measured inflammatory mediators alongside re-epithelialization (Sosne et al., 2001). Distinguishing a direct effect on epithelial cells from an indirect effect through reduced inflammation requires experiments that vary each factor independently, for example cell-autonomous migration assays alongside in vivo models with controlled inflammatory challenge.
Reading wound data: a short checklist
Before relying on a wound-healing figure, check the following. Was the number of animals per group stated and adequate? Was scoring blinded? Was the control a vehicle matched for volume, pH and carrier? Were wound areas measured at several time points, or only at the end? Were all animals analyzed, and were any excluded? Was a power calculation described? Wound size varies between animals, so using each animal’s initial size as the baseline and expressing closure as a percentage is standard. Where the paper reports only a representative image, regard the claim as qualitative.
What the animal studies do not show
Several limits apply. The studies used full-length thymosin β4. They were conducted in rodents, whose skin differs from other species. Each reports a limited set of wound types and time points. Most were performed by or with the group that originally characterized the molecule, so independent replication is needed to regard any single result as settled. And they speak only to the endpoints measured; they do not establish a mechanism in vivo, though in vitro studies of actin binding and migration provide candidates (Sun et al., 1996; Huff et al., 2001).
For the TB-500 fragment specifically, none of these studies tested it. A statement such as “TB-500 accelerated wound healing in rats” would therefore misattribute a result. The accurate statement is that thymosin β4 was reported to accelerate wound healing in rats and that the fragment is studied for its actin-binding region.
Designing a fragment-versus-protein comparison
A laboratory that wants to know whether the fragment recapitulates the protein’s effects can design the comparison directly. In vitro, a scratch-wound or transwell migration assay in keratinocytes or fibroblasts can include full-length thymosin β4, the fragment, a scrambled-sequence fragment and vehicle at matched molar concentrations. Molar matching matters because the two differ roughly sixfold in molecular weight: molar concentration is mass concentration divided by molar mass, so equal mass gives very different numbers of molecules. Concentration arithmetic here is formula-only (mg/mL equals vial mass in mg divided by diluent volume in mL), and the calculator handles volumes. Handling details are in TB-500 versus thymosin β4 and the general guide on reconstituting lyophilized peptides. Storage per the product page: refrigerate at 2–8 °C, −20 °C for long-term, protect from heat, moisture and light.
| Arm | Purpose |
|---|---|
| Vehicle only | Baseline migration or closure |
| Full-length thymosin β4 | Reference for the published protein effect |
| TB-500 fragment, molar matched | Test of the fragment against the protein |
| Scrambled-sequence control | Sequence specificity of any fragment effect |
| Positive control with known migration effect | Assay validity |
Related material
Other articles in the library place the compound in context: TB-500 versus BPC-157, TB-500 purity testing and the BPC-157 and TB-500 combination overview. Lot certificates, where published, are in the COA library. All material is for laboratory research use only.
Frequently asked questions
Were TB-500 wound-healing studies done in animals?
The animal wound-healing studies used full-length thymosin β4, not the TB-500 fragment. The fragment’s own effects were not tested in those papers.
What species were used?
Rats for the dermal wound study and mice for the corneal study, among rodent models described in related commentary.
What did the rat study report?
That thymosin β4, given topically or intraperitoneally, accelerated re-epithelialization and wound contraction compared with saline controls (Malinda et al., 1999).
What did the corneal study report?
That thymosin β4 promoted corneal wound healing in mice and modulated inflammatory mediators (Sosne et al., 2001).
What is TB-500 chemically?
Per the product page, the synthetic 17–23 fragment of thymosin β4, Ac-LKKTETQ, formula C38H68N10O14.
Why does the full-length versus fragment difference matter?
Results from a 43-residue protein cannot be assumed to apply to a seven-residue fragment that lacks most of its sequence.
Why is splinting relevant in rodent wound models?
Rodent skin heals largely by contraction, so splinting is used to favor epithelial and granulation-tissue processes.
How should concentrations be matched in a comparison?
On a molar basis, since the protein and fragment differ roughly sixfold in molecular weight; molar concentration equals mass concentration divided by molar mass.
How is the vial stored?
As the product page states: refrigerate at 2–8 °C, −20 °C for long-term, and protect from heat, moisture and light.
Where can I find the original papers?
The references list gives DOIs for each cited study; dose, vehicle and timing details are in the originals.
Related reading: How to Reconstitute TB-500: A Laboratory Guide, TB-500 Preclinical Studies: Fragment vs Thymosin Beta-4, History of TB-500 and Thymosin β4 Research.
References
- Malinda KM, Sidhu GS, Mani H, et al. Thymosin β4 accelerates wound healing. J Invest Dermatol. 1999;113(3):364-368. doi:10.1046/j.1523-1747.1999.00708.x
- Sosne G, Chan CC, Thai K, et al. Thymosin beta 4 promotes corneal wound healing and modulates inflammatory mediators in vivo. Exp Eye Res. 2001;72(5):605-608. doi:10.1006/exer.2000.0985
- Philp D, Goldstein AL, Kleinman HK. Thymosin β4 promotes angiogenesis, wound healing, and hair follicle development. Mech Ageing Dev. 2004;125(2):113-115. doi:10.1016/j.mad.2003.11.005
- Sun HQ, Kwiatkowska K, Yin HL. β-Thymosins are not simple actin monomer buffering proteins. J Biol Chem. 1996;271(16):9223-9230. doi:10.1074/jbc.271.16.9223
- Huff T, Müller CS, Otto AM, Netzker R, Hannappel E. β-Thymosins, small acidic peptides with multiple functions. Int J Biochem Cell Biol. 2001;33(3):205-220. doi:10.1016/s1357-2725(00)00087-x
- Goldstein AL, Hannappel E, Sosne G, Kleinman HK. Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opin Biol Ther. 2012;12(1):37-51. doi:10.1517/14712598.2012.634793
